Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PULSAR Combined With Sintilimab, Bevacizumab, and Chemotherapy for Colorectal Cancer Liver Metastasis
NCT06788171Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- May 2026
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, bevacizumab, capecitabine and oxaliplatin in colorectal cancer (CRC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Progression-Free Survival at 36 months. Started May 2026; status: recruiting.
02
Drugs
sintilimabbevacizumabcapecitabineoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06788171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06788171.